01 October 2020 | News
ABEC’s Custom Single Run (CSR®) technology to support production of ~1 billion doses of Novavax COVID-19 vaccine
Image credit- shutterstock.com
ABEC, a leading global provider of integrated solutions and services for biopharmaceutical manufacturing based in the US, has announced it is supporting Serum Institute of India Pvt. Ltd. (SIIPL) in Pune by delivering six 4,000L CSR bioreactors for the manufacturing of Novavax’ COVID-19 vaccine candidate, NVX‑CoV2373.
Serum Institute, the world’s largest vaccine manufacturer by number of doses, will utilize ABEC’s single-use technologies to advance a global supply of NVX‑CoV2373 throughout India and low- and middle-income countries.
Serum Institute’s new facility will be the largest single-use bioreactor-based vaccine manufacturing line in the world. ABEC’s 4,000L CSR single-use bioreactors are the largest in the industry by a factor of two, allowing Serum Institute to double productivity per unit floorspace and achieve the lowest possible cost per dose.
Leveraging its global presence, ABEC is manufacturing the single-use bioreactors and disposable containers (DC) in its US and Ireland facilities to meet Serum Institute’s accelerated schedule. ABEC’s multi-site global ISO-7 cleanrooms ensure a robust supply chain with the industry’s shortest DC lead times, enabling Serum Institute to begin production in early 2021.